Maged Shenouda, Chief Financial Officer at Relmada Therapeutics, bought RLMD on Sep 9, 2026

Data as of Oct 16

▲ BUY$505K120,200 shares at $4.20Maged Shenouda Chief Financial OfficerRLMD Relmada Therapeutics, Inc.

Watch RLMD

Traded: Sep 9, 2026
Disclosed: Sep 11, 2026
Filed: 2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

RLMDSimilar stocks (XLV — its sector index fund), rebased to RLMD's price on the disclosure day

RLMD since disclosure

−31.4%

Similar stocks (XLV) since disclosure

+6.9%

XLV — its sector index fund

Change in closing price from Sep 11, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

⚪ CFO buys $25K+ of own stock — fired on this trade
Not enough evidence · In past tests: 3.6 percentage points better than similar stocks over 3 months · 2,178 tries
⚪ CFO buys $25K+ of own liquid stock — fired on this trade
Not enough evidence · In past tests: 2.0 percentage points better than similar stocks over 3 months · 1,426 tries

What this rule is doing with RLMD right now

See pricing →

Already a member? Sign in

Other trades in the same filing

▲ BUYMaged Shenouda Chief Financial OfficerRLMD Relmada Therapeutics, Inc.$339Kdisclosed Sep 11 · filed 1 day after the trade 2 rules fired

See every trade on RLMD →